Verve Therapeutics, Inc. (VERV)
NASDAQ: VERV · Real-Time Price · USD
5.76
-0.02 (-0.35%)
At close: Apr 25, 2025, 4:00 PM
5.75
-0.01 (-0.17%)
After-hours: Apr 25, 2025, 5:33 PM EDT
Verve Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Verve Therapeutics stock have an average target of 25.75, with a low estimate of 15 and a high estimate of 39. The average target predicts an increase of 347.05% from the current stock price of 5.76.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Verve Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Hold → Buy Upgrades n/a | Hold → Buy | Upgrades | n/a | n/a | Apr 15, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $18 → $24 | Strong Buy | Maintains | $18 → $24 | +316.67% | Apr 15, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $32 → $39 | Strong Buy | Maintains | $32 → $39 | +577.08% | Apr 15, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $15 → $25 | Strong Buy | Maintains | $15 → $25 | +334.03% | Apr 14, 2025 |
| Guggenheim | Guggenheim | Strong Buy Reiterates n/a | Strong Buy | Reiterates | n/a | n/a | Mar 25, 2025 |
Financial Forecast
Revenue This Year
24.64M
from 32.33M
Decreased by -23.81%
Revenue Next Year
13.17M
from 24.64M
Decreased by -46.54%
EPS This Year
-2.78
from -2.35
EPS Next Year
-2.72
from -2.78
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 54.9M | 33.6M | 47.3M | ||
| Avg | 24.6M | 13.2M | 13.9M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 69.9% | 36.4% | 258.7% | ||
| Avg | -23.8% | -46.5% | 5.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.43 | -2.28 | -2.02 | ||
| Avg | -2.78 | -2.72 | -2.53 | ||
| Low | -3.10 | -3.03 | -3.33 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.